Background. Androgen deprivation has been in use for the treatment of advanced prostate cancer since 1941; however, most patients develop resistance to treatment leading to incurable, androgen-independent disease. Previous reports have correlated endothelin A receptor (ETA) expression with increasing prostate cancer grade and stage, and have shown that endothelin-1 (ET-1) treatment of ETA-expressing prostate cancer cells inhibits apoptosis. ETA blockade has emerged as a potential strategy in the treatment of advanced prostate cancer. Here, the potential role of endothelin signaling in promoting prostate cancer cell survival during androgen ablation therapy is evaluated in efforts to establish the potential value of ETA blockade in improving hormone therapy.
Methodology and Principle Findings. Androgen-dependent human prostate cancer cells were androgen deprived and evaluated for expression changes in ET-1, ETA, ETB, and AR. Ligand binding, real time quantitative PCR, and immunohistochemical studies show that androgen deprivation increased ET-1, ETA, ETB, and AR expression in prostate cancer cell lines, and ETA expression in human prostate tissue. Using the specific AR inhibitor bicalutamide, acute androgen receptor blockade increased prostate cancer cell ET-1 secretion. Following androgen deprivation, LNCaP cells acquired androgen independence (LNCaP-AI), but retained sensitivity to androgens. ET-1 treatment of ETA over-expressing prostate cancer cells induced a more rapid and sustained activation of Akt, and ETA blockade significantly reduced Akt activation. In vivo ETA blockade, in combination with castration, significantly reduced LNCaP xenograft cell growth, compared to either treatment alone. Affymetrix GeneChip HG-U133 Plus 2 expression array analysis of androgen deprived prostate cancer cells discovered dramatic changes in gene expression patterns throughout the transition to androgen independence. Lastly, the role of ETB signaling in prostate cancer cell apoptosis was examined but remains to be further elucidated.
Conclusions and Significance. During androgen deprivation, prostate cancer cells up-regulate ET-1 and ETA expression. Upon engagement of ET-1, ETA invokes activation of the survival factor Akt. In vivo, ETA blockade plus castration inhibits prostate cancer growth. Collectively, these results implicate endothelin survival signaling in promoting progression to androgen-independent disease, and lend support to the targeted disruption of endothelin survival signaling in treating advanced, metastatic prostate cancer.
| Identifer | oai:union.ndltd.org:PITT/oai:PITTETD:etd-08292007-110716 |
| Date | 29 August 2007 |
| Creators | D'Antonio, Jason M. |
| Contributors | Beth R. Pflug, Ph.D., Michael J. Becich, M.D., Ph.D., Alan Wells, M.D., D.M.S., Billy Day, Ph.D., Luyuan Li, Ph.D. |
| Publisher | University of Pittsburgh |
| Source Sets | University of Pittsburgh |
| Language | English |
| Detected Language | English |
| Type | text |
| Format | application/pdf |
| Source | http://etd.library.pitt.edu/ETD/available/etd-08292007-110716/ |
| Rights | unrestricted, I hereby certify that, if appropriate, I have obtained and attached hereto a written permission statement from the owner(s) of each third party copyrighted matter to be included in my thesis, dissertation, or project report, allowing distribution as specified below. I certify that the version I submitted is the same as that approved by my advisory committee. I hereby grant to University of Pittsburgh or its agents the non-exclusive license to archive and make accessible, under the conditions specified below, my thesis, dissertation, or project report in whole or in part in all forms of media, now or hereafter known. I retain all other ownership rights to the copyright of the thesis, dissertation or project report. I also retain the right to use in future works (such as articles or books) all or part of this thesis, dissertation, or project report. |
Page generated in 0.0015 seconds